Daytime Sleepiness (Credit: Canva)
Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually
affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.
For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.
The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.
To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.
There are many types of dementia:
Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.
Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.
In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.
Credit: AI
Nearly 94% of tuberculosis (TB) patients in an Indian study conducted in Bengaluru reported anxiety symptoms, while 77.3% showed signs of depression. The findings focus on the mental health toll that comes with TB. It also sheds light on the need to include psychological support in routine treatment of tuberculosis.
The cross-sectional study, conducted with 66 adults at the Yeshwanthpur Tuberculosis Unit in Bengaluru, found that 56.1% had moderate to severe anxiety symptoms, while 46.9% had moderate to severe depressive symptoms. Nearly half of the participants experienced symptoms of both conditions.
The study was conducted by Dr. Pavithra Cheluvaraj, Dr. Vishnu C. Sudhakaran, Dr. Babitha Rajan and Anjana Sasikumar Nair from the Department of Community Medicine at Ramaiah Medical College.
The researchers examined the patients using the Patient Health Questionnaire-9 (PHQ-9) and the Generalised Anxiety Disorder-7 (GAD-7) scales.
Stigma linked with TB, fear of transmitting the infection to family members and existing health conditions may contribute to anxiety and depression among patients, Dr. Pavithra told Bangalore Mirror.
TB treatment can also entail a prolonged course of medication and regular follow-up. Psychological distress may make it harder for patients to continue treatment or seek timely care.
According to Dr. Pavithra, anxiety and depression if left untreated could affect the course of TB treatment. Patients experiencing psychological distress may delay starting treatment or stop taking their medication, which could compromising recovery and increasing the risk of drug resistance.
“If there is delay in diagnosis or treatment, the person can spread the disease,” she said.
Also read: You May Be Carrying TB, And Not Know Until It Gets Worse
The researchers used two standardised screening tools to assess symptoms of depression and anxiety.
The PHQ-9 measures depressive symptoms, while the GAD-7 tests for symptoms of anxiety. The study found that 51 of the 66 participants had symptoms linked with depression, and 62 had symptoms that indicated anxiety.
Moderate to severe symptoms were found in 31 participants for depression and 37 for anxiety. These screening results indicate the need for further clinical assessment. The findings are merely observations and they do not mean that every participant had a confirmed psychiatric diagnosis of anxiety and depression.
Additionally, the study was based on 66 adults in one tuberculosis unit in Bengaluru, so its findings cannot represent all TB patients in India.
But the high percentage of participants who reported symptoms of anxiety and depression suggest that there is need for better integration of mental health screening into TB treatment.
The researchers recommended routine screening for depression and anxiety when patients are diagnosed with TB and during follow-up visits. They also called for counselling and referrals for patients with more severe symptoms.
They say that identifying psychological distress early may help doctors connect patients with appropriate support while they receive treatment for the infection.
Even though this study is based on a small sample, it speaks about the long-term effects of the disease on mental health. TB is a global health crisis, which means this study warrants further investigation and action.
According to the WHO’s Global Tuberculosis Report 2025, in 2024, more than ten million people across the globe developed TB while more than 1.2 million lost their lives to the disease.
Currently, India bears the lion's share of TB burden compared to other countries. Uneven access to drug-resistant TB treatment, financial hardships, stigma, prolonged treatment are some of the factors that may contribute to deteriorating mental health of TB patients.
Credit: iStock
GLP-1 medications, widely prescribed for diabetes and weight loss, may also be associated with a lower risk of serious complications after surgery, a new study suggests.
The study, involving more than 2 million adults undergoing surgery, found that people taking GLP-1 medications had lower rates of major cardiovascular complications and postoperative infections than those not taking the drugs. Researchers from the University of Texas Health Houston presented the findings at the Anesthesiology 2026 annual meeting.
"GLP-1 medications have become part of everyday care for many people with diabetes or obesity, but physicians still need more evidence about how these drugs affect patients around the time of surgery," said lead author Josephine Tolan, an anesthesiologist at the Center for Outcomes Research, Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School at UTHealth Houston.
Tolan added that although the results are encouraging, more research is needed to determine if the medications themselves are driving these benefits and how best to manage them before and after surgery.
Also read: Exclusive: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor
Researchers analyzed data from the Epic Cosmos database, a de-identified electronic health record database covering more than 1,700 hospitals and 40,000 clinics.
The study included US adults aged 18 and older who underwent elective surgeries lasting more than 60 minutes and stayed in the hospital for at least 24 hours after surgery between January 2016 and December 2024. Of the 2,028,601 patients included, 145,610, or about 7%, were taking GLP-1 medications.
After matching GLP-1 users with similar patients who were not taking the drugs, researchers found that GLP-1 use was associated with:
Read More: GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study
Previous research has shown that GLP-1 medications can lower the risk of cardiovascular problems in some patients. However, their effects during and after surgery remain less clear.
Surgery places stress on the body, can trigger inflammation and may cause changes in blood pressure, blood sugar and circulation, potentially increasing the risk of cardiovascular complications and infections, the researchers explained.
Further, they suggest that GLP-1 medications may be associated with fewer cardiovascular complications because they support weight loss, improve blood pressure and blood sugar control, reduce inflammation and may protect heart muscle during periods of stress.
These medications may also help reduce infection risk by improving blood sugar control. High blood sugar can weaken the body's immune response, making it harder to fight infections.
READ: Ozempic Baby: Can GLP-1 Drugs Help Women With PMOS Conceive?
Research has found that people taking GLP-1 medications to treat diabetes, overweight or obesity have fewer major cardiovascular events, like heart attack or stroke, compared to people not taking GLP-1 medications.
In fact, the American College of Cardiology now recommends GLP-1 drugs as a way to reduce cardiovascular disease risk through weight loss.
When weight decreases, so does blood pressure, inflammation, LDL (bad) cholesterol and triglycerides, and protective factors like good (HDL) cholesterol increase. In other words, overweight or obese individuals who are prescribed a GLP-1 for weight loss may experience positive changes to their heart health, especially if they are at risk of heart disease.
Credit: AI
Smokeless tobacco accounted for 57.3% of mouth cancers among men in India, while tobacco in any form estimated to be at least 73.4% of mouth cancers among women, according to a new study published in the Indian Journal of Medical Research.
The study, Head and Neck Cancer Burden Attributable to Tobacco Use in India: National and Region-wise Estimates, sheds light on the differences in tobacco-related cancer risks by sex, cancer site and region. The findings also bring attention to the role of smokeless tobacco products and their contribution to head and neck cancer burden in India.
The researchers estimated that eliminating tobacco exposure could prevent a bulk proportion of these cancers.
Researchers studied records of 11,285 patients diagnosed with head and neck cancers and 7,154 people with non-cancerous conditions who visited the Regional Cancer Centre in Thiruvananthapuram, Kerala, India between 2019 and 2024.
Among men, smokeless tobacco accounted for 61.8% of lip cancers, 30.7% of tongue cancers and 57.3% of mouth cancers.
On the other hand, almost 40.2% of cancers of the base of the tongue, tonsils and oropharynx, 45.7% of hypopharyngeal cancers and 38.4% of laryngeal cancers were attributed to smoking.
The authors highlighted how smoking and smokeless tobacco expose oral tissues to carcinogens. The authors wrote, “This may be because smokeless tobacco directly contacts the oral cavity, causing prolonged exposure of the tongue to carcinogens, whereas smoking produces more diffuse and less concentrated exposure.”
The study also found that 55.3% of men with mouth cancer used smokeless tobacco, compared to 17.5% of men in the comparison group. Among men diagnosed with hypopharyngeal cancer, 85% smoked.
Among women, smokeless tobacco accounted for around 68.8% of lip cancers and 68% of mouth cancers. Smoking accounted for 41% of oropharyngeal cancers and 34% of hypopharyngeal cancers.
The researchers estimated that the odds of mouth cancer among women who used smokeless tobacco were 17.6 times those among non-users. Among men, the corresponding odds ratio was 5.5.
The study also shows differences in tobacco-related cancer risks between states. Among men, the estimated proportion of mouth cancers due to smokeless tobacco was 71% in Jharkhand and 70.3% in Odisha.
In southern India, the estimates were 50.2% in Karnataka, 35.1% in Tamil Nadu, 33.9% in Telangana, 25.6% in Andhra Pradesh and 25.1% in Kerala.
Among women, the estimated proportion of mouth cancers due to smokeless tobacco exceeded 80% in Chhattisgarh, Odisha and several Northeastern states. In Tripura, it was around 90.4%.
The authors said that these differences could be due to regional variations in tobacco consumption and the products used.
However, the study used cancer risk estimates derived from hospital-based data in Kerala and applied them nationally because state-specific risk estimates were unavailable.
The authors addressed this limitation, stating, “In this study, due to limited State-specific data, cancer risk from tobacco exposures was assumed uniform nationwide.”
The researchers stressed the need for prevention by improving access to tobacco cessation services, especially in regions with high estimated burdens of tobacco-related cancers.
“The findings emphasise the need to strengthen tobacco cessation services, especially for high-risk men in regions with elevated population attributable fractions,” the authors wrote.
© $2026 Times Horizon Private Limited